ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+1.24%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$119M
AUM Growth
+$119M
(-23%)
Cap. Flow
-$20.5M
Cap. Flow
% of AUM
-17.25%
Top 10 Holdings %
Top 10 Hldgs %
65.36%
Holding
42
New
8
Increased
12
Reduced
9
Closed
9
Top Buys
| 1 |
Corbus Pharmaceuticals
CRBP
|
$2.92M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$2.54M |
| 3 |
BBOT
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
|
$1.82M |
| 4 |
argenx
ARGX
|
$1.72M |
| 5 |
Kura Oncology
KURA
|
$1.5M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$5.79M |
| 2 |
Applied Therapeutics
APLT
|
$5.39M |
| 3 |
Disc Medicine
IRON
|
$4.78M |
| 4 |
Celldex Therapeutics
CLDX
|
$4.57M |
| 5 |
HilleVax
HLVX
|
$4.17M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$2.12B
| $19M | 15.96% | 2,771,130 +135,843 | +5% | +$929K |
|
2
Enliven Therapeutics
ELVN
$1.2B
| $9.29M | 7.83% | 397,698 +1,599 | +0.4% | +$37.4K |
|
3
Vaxcyte
PCVX
$4B
| $8.34M | 7.02% | 110,400 +5,570 | +5% | +$421K |
|
4
Dyne Therapeutics
DYN
$1.92B
| $7.5M | 6.32% | 212,500 +28,000 | +15% | +$988K |
|
5
Praxis Precision Medicines
PRAX
$958M
| $6.8M | 5.73% | 164,431 +2,129 | +1% | +$88.1K |
|
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $6.05M | 5.1% | 135,141 +56,738 | +72% | +$2.54M |
|
7
Rocket Pharmaceuticals
RCKT
$354M
| $5.39M | 4.54% | 250,370 -76,417 | -23% | -$1.65M |
|
8
Taysha Gene Therapies
TSHA
$797M
| $5.22M | 4.4% | 2,330,937 -1,002,396 | -30% | -$2.25M |
|
9
Revolution Medicines
RVMD
$7.1B
| $5.16M | 4.35% | 133,000 -10,777 | -7% | -$418K |
|
10
Insmed
INSM
$28.8B
| $4.83M | 4.07% | 72,100 +10,382 | +17% | +$696K |
|
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $4.35M | 3.66% | 27,500 -36,662 | -57% | -$5.79M |
|
12
Tourmaline Bio
TRML
$601M
| $3.47M | 2.92% | 269,614 +8,506 | +3% | +$109K |
|
13
Agios Pharmaceuticals
AGIO
$2.19B
| $3.39M | 2.86% | 78,700 +23,438 | +42% | +$1.01M |
|
|
14
Kura Oncology
KURA
$686M
| $3.36M | 2.83% | 163,000 +73,000 | +81% | +$1.5M |
|
15
Mersana Therapeutics
MRSN
$36.5M
| $3.34M | 2.82% | 1,663,000 -501,628 | -23% | -$1.01M |
|
|
16
Corbus Pharmaceuticals
CRBP
$115M
| $2.92M | 2.46% | +64,500 | New | +$2.92M |
|
|
WHWK
17
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $2.7M | 2.27% | 1,849,402 | – | – |
|
18
Viridian Therapeutics
VRDN
$1.5B
| $2.59M | 2.19% | 199,433 | – | – |
|
19
Terns Pharmaceuticals
TERN
$609M
| $2.51M | 2.12% | 369,280 -95,799 | -21% | -$652K |
|
|
MREO
20
Mereo BioPharma
MREO
$272M
| $2.44M | 2.05% | 677,000 +279,116 | +70% | +$1M |
|
21
Arcellx
ACLX
$3.85B
| $2.33M | 1.96% | 42,200 +7,700 | +22% | +$425K |
|
|
BBOT
22
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $1.82M | 1.53% | +177,836 | New | +$1.82M |
|
|
23
argenx
ARGX
$43.6B
| $1.72M | 1.45% | +4,000 | New | +$1.72M |
|
24
Trevi Therapeutics
TRVI
$883M
| $775K | 0.65% | +260,000 | New | +$775K |
|
25
Celcuity
CELC
$2.17B
| $737K | 0.62% | +45,000 | New | +$737K |
|